^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Gastric Cancer
    Drug:AST-301 (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Biological Therapy in Treating Patients With Advanced Cancer

    Excerpt:
    ...- Histologically confirmed advanced malignancy that expresses HER2/neu...
    Trial ID:
    NCT00005956
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    J Immunother Cancer
    Title:

    776 The anti-tumor activity of HER-2/neu ICD therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in Her2-expressed gastric cancer xenograft model

    Published date:
    11/24/2021
    Excerpt:
    Tumor protective effect was observed in AST-301 group (1506.7±1603.0 mm3) compared with control group (GM-CSF, 1266.3±862.5 mm3) as an immune adjuvant...The groups of AST-301 and AST-301+TZM were significantly higher to the anti-tumor activity than control group, and AST-301 was more effective than AST-301+TZM or TZM alone…. Tumor protective and tumor therapeutic effect of AST-301 were demonstrated well in various doses and regimens on HER2/neu positive gastric cancer xenograft model.
    DOI:
    http://dx.doi.org/10.1136/jitc-2021-SITC2021.776